サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1785919

カペシタビンの世界市場

Capecitabine

出版日
ページ情報
英文 220 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
カペシタビンの世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 220 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

カペシタビンの世界市場は2030年までに5億2,870万米ドルに達する見込み

2024年に4億2,740万米ドルと推定されるカペシタビンの世界市場は、2024年から2030年にかけてCAGR 3.6%で成長し、2030年には5億2,870万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学ベースAPIは、CAGR4.3%を記録し、分析期間終了時には2億3,350万米ドルに達すると予測されます。生物学的APIセグメントの成長率は、分析期間でCAGR 3.3％と推定されます。

米国市場は1億1,640万米ドルと推定、中国はCAGR6.8％で成長予測

米国のカペシタビン市場は、2024年に1億1,640万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億660万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.8%と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界のカペシタビン市場：主要動向と促進要因のまとめ

カペシタビン市場の成長を促進しているものは？

カペシタビンの世界市場は、がん罹患率の増加や効果的な化学療法治療に対する需要の高まりにより、着実な成長を遂げています。経口化学療法薬であるカペシタビンは、大腸がん、乳がん、胃がんの治療に広く使用されており、がん管理プロトコルの重要な構成要素となっています。ライフスタイルの変化、人口の高齢化、遺伝的素因などにより、がん患者は増加傾向にあり、効果的で忍容性の高い治療オプションに対するニーズは高まり続けています。静脈内投与よりも経口化学療法が好まれることも、患者にとって利便性が高く、通院の必要性を減らすことができるため、カペシタビンの使用拡大につながっています。

オンコロジーの進歩は、カペシタビンの普及をどのように後押ししているのでしょうか？

現在進行中の調査や臨床試験では、併用療法におけるカペシタビンの有効性が検討されています。カペシタビンはしばしば他の化学療法剤や標的治療薬と併用され、治療成績を高め、患者の生存率を向上させます。個別化医療やバイオマーカー主導のがん治療における革新もカペシタビン市場に影響を与えており、がん専門医が個々の患者プロファイルに基づいて治療レジメンを調整するようになってきています。さらに、薬剤の効能を向上させ、副作用を最小限に抑えるための新しい製剤や徐放性製剤の開発も進んでおり、患者にとっても医療従事者にとっても、より魅力的な選択肢となっています。

なぜ新興ヘルスケア市場で市場が成長しているのか？

カペシタビン市場は、特にがん罹患率が上昇しているアジア太平洋やラテンアメリカなどの新興ヘルスケア市場で大きな成長を遂げています。ヘルスケアへのアクセスの改善、がん治療に対する政府のイニシアチブの増加、医薬品流通網の拡大により、カペシタビンはより多くの患者にとって利用しやすいものとなっています。さらに、カペシタビンのジェネリック医薬品が手頃な価格で手に入るようになったことで、低・中所得国でも広く採用されるようになりました。がん治療施設の拡大や早期発見・治療に対する意識の高まりにより、カペシタビンの需要は世界市場全体で安定的に成長すると予想されます。

市場拡大を促す要因とは？

カペシタビン市場の成長は、いくつかの要因によって牽引されています。世界のがん罹患率の上昇と、一次治療の選択肢として化学療法への注目が高まっていることが、市場の需要を大きく押し上げています。患者中心の治療アプローチへのシフトにより、カペシタビンのような経口化学療法薬への嗜好が高まっており、静脈内療法と比較して投与が容易でQOLが向上しています。また、規制当局の承認や現在進行中の併用療法に関する調査により、薬剤の適用範囲が拡大し、市場の可能性が高まっています。さらに、ヘルスケア投資の増加と費用対効果の高いジェネリック製剤の導入により、カペシタビンは多様な層で利用しやすくなっており、市場の持続的成長に寄与しています。

セグメント

合成タイプ（化学ベースAPI、生物学的API、高活性API（HPAPI））、適応症（乳がん、大腸がん、胃がん、膵がん、その他の適応症）

調査対象企業の例

  • Accord Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Drugs Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • MSN Laboratories Pvt. Ltd.
  • Mylan N.V.
  • Reliance Life Sciences Pvt. Ltd.
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29792

Global Capecitabine Market to Reach US$528.7 Million by 2030

The global market for Capecitabine estimated at US$427.4 Million in the year 2024, is expected to reach US$528.7 Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Chemical-based API, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$233.5 Million by the end of the analysis period. Growth in the Biological API segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$116.4 Million While China is Forecast to Grow at 6.8% CAGR

The Capecitabine market in the U.S. is estimated at US$116.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$106.6 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Capecitabine Market: Key Trends & Drivers Summarized

What Is Fueling the Growth of the Capecitabine Market?

The global capecitabine market is witnessing steady growth, driven by the increasing prevalence of cancer and the rising demand for effective chemotherapy treatments. Capecitabine, an oral chemotherapy drug, is widely used for the treatment of colorectal, breast, and gastric cancers, making it a crucial component of cancer management protocols. With cancer cases on the rise due to lifestyle changes, aging populations, and genetic predispositions, the need for effective and well-tolerated treatment options continues to grow. The preference for oral chemotherapy over intravenous administration has further contributed to the expanding use of capecitabine, as it offers greater convenience for patients and reduces the need for hospital visits.

How Are Advancements in Oncology Boosting Capecitabine Adoption?

The field of oncology is undergoing rapid advancements, with ongoing research and clinical trials exploring the efficacy of capecitabine in combination therapies. Capecitabine is often used in conjunction with other chemotherapy agents or targeted therapies to enhance treatment outcomes and improve patient survival rates. Innovations in personalized medicine and biomarker-driven cancer therapies have also influenced the capecitabine market, as oncologists increasingly tailor treatment regimens based on individual patient profiles. Additionally, new drug formulations and extended-release versions are being developed to improve the drug’s efficacy and minimize side effects, making it a more attractive option for both patients and healthcare providers.

Why Is the Market Growing in Emerging Healthcare Markets?

The capecitabine market is witnessing significant growth in emerging healthcare markets, particularly in Asia-Pacific and Latin America, where cancer incidence rates are rising. Improved access to healthcare, increasing government initiatives for cancer treatment, and the expansion of pharmaceutical distribution networks have made capecitabine more accessible to a larger patient population. Additionally, the growing affordability of generic versions of capecitabine has enabled wider adoption in low- and middle-income countries. With the expansion of cancer care facilities and increased awareness about early detection and treatment, the demand for capecitabine is expected to grow steadily across global markets.

What Factors Are Driving Market Expansion?

The growth in the capecitabine market is driven by several factors. The rising global burden of cancer and the increasing focus on chemotherapy as a primary treatment option have significantly boosted market demand. The shift towards patient-centric treatment approaches has led to a growing preference for oral chemotherapy drugs like capecitabine, which offer ease of administration and improved quality of life compared to intravenous therapies. Regulatory approvals and ongoing research into combination therapies have also expanded the drug’s applicability, enhancing its market potential. Additionally, increasing healthcare investments, coupled with the introduction of cost-effective generic formulations, are making capecitabine more accessible across diverse demographics, contributing to sustained market growth.

SCOPE OF STUDY:

The report analyzes the Capecitabine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Synthesis Type (Chemical-based API, Biological API, Highly Potent API (HPAPI)); Indication (Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Accord Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Drugs Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • MSN Laboratories Pvt. Ltd.
  • Mylan N.V.
  • Reliance Life Sciences Pvt. Ltd.
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Capecitabine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Colorectal and Breast Cancer Fueling Drug Demand
    • Growing Preference for Oral Chemotherapy Agents Enhancing Patient Compliance
    • Expansion of Targeted Therapy and Combination Regimens Increasing Usage
    • Increased Focus on Home-Based Cancer Treatment Modalities
    • Wider Drug Access Through National Cancer Care Programs in Emerging Economies
    • Ongoing Clinical Trials Supporting Expanded Indications for Capecitabine
    • Rising Geriatric Population Driving Long-Term Cancer Treatment Needs
    • Technological Advancements in Oncology Diagnostics Boosting Treatment Personalization
    • Improved Availability of Generics Increasing Affordability in Developing Markets
    • Healthcare Infrastructure Development Supporting Greater Drug Access
    • Supportive Reimbursement Frameworks in Developed Markets Driving Prescriptions
    • Growth in Awareness of Early Cancer Detection Elevating First-Line Therapy Demand
    • Increased Oncology R&D Pipelines Encouraging Adjunctive Use of Capecitabine
    • Collaborations Between Pharma Companies Enhancing Market Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Capecitabine Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Chemical-based API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Chemical-based API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Biological API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Biological API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Highly Potent API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Highly Potent API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • JAPAN
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • CHINA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 34: China Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • EUROPE
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • FRANCE
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 42: France Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 44: France Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • GERMANY
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 54: UK Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 56: UK Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • SPAIN
    • TABLE 58: Spain Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Spain 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 60: Spain Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Spain 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • RUSSIA
    • TABLE 62: Russia Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Russia 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 64: Russia Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Russia 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of Europe 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 68: Rest of Europe Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Europe 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 71: Asia-Pacific 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Asia-Pacific 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 74: Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Asia-Pacific 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • AUSTRALIA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 76: Australia Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Australia 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 78: Australia Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Australia 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • INDIA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 80: India Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: India 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 82: India Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: India 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 84: South Korea Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: South Korea 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 86: South Korea Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: South Korea 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 88: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Asia-Pacific 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 90: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Asia-Pacific 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • LATIN AMERICA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 92: Latin America Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Latin America 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 94: Latin America Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Latin America 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 96: Latin America Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Latin America 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 98: Argentina Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Argentina 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 100: Argentina Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Argentina 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • BRAZIL
    • TABLE 102: Brazil Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Brazil 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 104: Brazil Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Brazil 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • MEXICO
    • TABLE 106: Mexico Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Mexico 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 108: Mexico Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Mexico 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 110: Rest of Latin America Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Latin America 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 112: Rest of Latin America Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Latin America 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • MIDDLE EAST
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 114: Middle East Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 115: Middle East 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 116: Middle East Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Middle East 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 118: Middle East Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Middle East 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • IRAN
    • TABLE 120: Iran Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Iran 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 122: Iran Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Iran 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • ISRAEL
    • TABLE 124: Israel Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Israel 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 126: Israel Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Israel 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 128: Saudi Arabia Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Saudi Arabia 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 130: Saudi Arabia Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Saudi Arabia 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 132: UAE Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: UAE 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 134: UAE Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UAE 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 136: Rest of Middle East Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of Middle East 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 138: Rest of Middle East Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of Middle East 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • AFRICA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 140: Africa Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Africa 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 142: Africa Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Africa 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030

IV. COMPETITION